CN106687596A - 微生物学方法 - Google Patents

微生物学方法 Download PDF

Info

Publication number
CN106687596A
CN106687596A CN201580020145.0A CN201580020145A CN106687596A CN 106687596 A CN106687596 A CN 106687596A CN 201580020145 A CN201580020145 A CN 201580020145A CN 106687596 A CN106687596 A CN 106687596A
Authority
CN
China
Prior art keywords
migalastat
streptomyces
fermentation
galactostatin
microorganism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580020145.0A
Other languages
English (en)
Chinese (zh)
Inventor
E.阿尔瓦雷茨-鲁伊斯
A.J.科利斯
A.S.丹恩
A.P.福斯伯里
S.J.雷迪
M.J.瓦兹奎兹穆尼兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN106687596A publication Critical patent/CN106687596A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/40—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving amylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580020145.0A 2014-02-17 2015-02-17 微生物学方法 Pending CN106687596A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382054 2014-02-17
EP14382054.6 2014-02-17
PCT/EP2015/053282 WO2015121488A1 (en) 2014-02-17 2015-02-17 Microbiological process

Publications (1)

Publication Number Publication Date
CN106687596A true CN106687596A (zh) 2017-05-17

Family

ID=50150672

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580020145.0A Pending CN106687596A (zh) 2014-02-17 2015-02-17 微生物学方法

Country Status (9)

Country Link
US (2) US10077458B2 (https=)
EP (1) EP3108002A1 (https=)
JP (1) JP2017506520A (https=)
KR (1) KR20160122206A (https=)
CN (1) CN106687596A (https=)
AU (1) AU2015216909B2 (https=)
CA (1) CA2939698A1 (https=)
RU (1) RU2016137120A (https=)
WO (1) WO2015121488A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116710185A (zh) * 2020-12-16 2023-09-05 阿米库斯治疗学公司 高度纯化批次的药品级1-脱氧半乳糖野尻霉素化合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150239584A1 (en) * 2014-02-26 2015-08-27 Elc Management Llc Aerosol Package With Fermentation Propulsion
CN106148216B (zh) 2015-03-27 2019-06-04 浙江海正药业股份有限公司 一种链霉菌及其生产米尔贝霉素a3的方法
EP3365458A1 (en) * 2015-10-21 2018-08-29 Novozymes A/S Direct inoculation
WO2022132992A1 (en) * 2020-12-16 2022-06-23 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2086394A (en) * 1980-10-27 1982-05-12 Shionogi Seiyaku Kk B-galctosidase inhibitor designated gt-2558 and derivatives thereof and microorganism for use in their preparation
JP2007055961A (ja) * 2005-08-26 2007-03-08 Mercian Corp １−デオキシガラクトノジリマイシンの製造方法、合成中間体およびその製造方法
CN101277969A (zh) * 2005-06-08 2008-10-01 阿米库斯治疗学公司 亚氨基糖和氨基糖的纯化
WO2012125402A2 (en) * 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
JP2012191899A (ja) * 2011-03-17 2012-10-11 Tohoku Univ アザ糖を生産する微生物
WO2012154681A1 (en) * 2011-05-06 2012-11-15 Amicus Therapeutics Quantitation of gl3 in urine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280472A (ja) * 1985-06-05 1986-12-11 Shionogi & Co Ltd β−ガラクトシダ−ゼ阻害物質ガラクトスタチン類およびその製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2086394A (en) * 1980-10-27 1982-05-12 Shionogi Seiyaku Kk B-galctosidase inhibitor designated gt-2558 and derivatives thereof and microorganism for use in their preparation
CN101277969A (zh) * 2005-06-08 2008-10-01 阿米库斯治疗学公司 亚氨基糖和氨基糖的纯化
JP2007055961A (ja) * 2005-08-26 2007-03-08 Mercian Corp １−デオキシガラクトノジリマイシンの製造方法、合成中間体およびその製造方法
WO2012125402A2 (en) * 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
JP2012191899A (ja) * 2011-03-17 2012-10-11 Tohoku Univ アザ糖を生産する微生物
WO2012154681A1 (en) * 2011-05-06 2012-11-15 Amicus Therapeutics Quantitation of gl3 in urine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BR ANDY YOUNG -GQAMANA 等: "Migalas tat HCl Reduces Globotri aosylsphingos ine (LysoGb3) in Fabry Transgenic Mice and in the Plasma of Fabry Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients", 《PLOS ONE》 *
WATSON J. LEES 等: "The Enzymatic Synthesis of 1,5-Dideoxy-1,5diimino-D-talitol and 1-Deoxygalactostatin Using Fuculose-I -phosphate Aldolase", 《BIOORGANIC CHEMISTRY 》 *
YUKIO MIYAKE 等: "Inhibition of β-Galactosidase by Galactostatin,Galactostatin-lactam, and 1-Deoxygalactostatin", 《AGRIC.BIOL.CHEM.》 *
YUKIO MIYAKE 等: "The Structures of a β-Galactosidase Inhibitor,Galactostatin, and Its Derivatives", 《AGRIC.BIOL.CHEM.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116710185A (zh) * 2020-12-16 2023-09-05 阿米库斯治疗学公司 高度纯化批次的药品级1-脱氧半乳糖野尻霉素化合物

Also Published As

Publication number Publication date
AU2015216909B2 (en) 2017-07-20
AU2015216909A1 (en) 2016-09-01
CA2939698A1 (en) 2015-08-20
JP2017506520A (ja) 2017-03-09
EP3108002A1 (en) 2016-12-28
RU2016137120A (ru) 2018-03-22
US20180208955A1 (en) 2018-07-26
KR20160122206A (ko) 2016-10-21
WO2015121488A1 (en) 2015-08-20
US20160355856A1 (en) 2016-12-08
US10077458B2 (en) 2018-09-18

Similar Documents

Publication Publication Date Title
US7507564B2 (en) Tiacumicin production
US20180208955A1 (en) Microbiological Process
JPH0764872B2 (ja) Ｆｒ９０１２２８物質およびその製造法
JP5916132B2 (ja) エクオールの製造方法
JPS61119195A (ja) クラブラン酸の製法
JP5996187B2 (ja) エクオールの製造方法
JPH0689012B2 (ja) Ｃｌ‐１５７７‐ｂ▲下４▼化合物およびその製法
JP2873894B2 (ja) 環状デプシペプチドおよびその製造法
CN113396214A (zh) 从链霉菌属sp.mcc-0151生产尼日利亚菌素的方法
HU194314B (en) Process for preparing new, alpha-glucosidase inhibiting pseudooligosaccharides
US6004995A (en) Macrolide compound 0406
US6693085B2 (en) Macrolide compound JK
SU697056A3 (ru) Способ получени антибиотического комплекса лизолипина
JPH0342075B2 (https=)
JPH07278055A (ja) 抗菌性物質ｂｅ−４０６６５類
GB2093017A (en) Polyene antibiotics
JPH08131186A (ja) 抗菌性物質ｂｅ−４３７６７類
JPS62277378A (ja) カズサマイシンｂ、その製造法およびその用途
JPH11140091A (ja) 生理活性物質ｎａ３２１７６ａ、その製造法およびその用途
JPH08231532A (ja) 抗菌性物質ｂｅ−４０６６５ｄ
JPH09143195A (ja) 新規化合物ａ−７４２５９
JPS61260888A (ja) 新規抗生物質ｓｆ−２３６１物質、その製造法及びその用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170517

WD01 Invention patent application deemed withdrawn after publication